Akhmal Yusof – CEO, Clinical Research Malaysia (CRM)
Dr Akhmal Yusof, CEO of CRM sheds light on the capacity for all stages of clinical research in Malaysia. He discusses the importance of human resources for the country’s research…
Clinical Research Malaysia (CRM) is a non-profit organization wholly owned by the Government of Malaysia. It was established in June 2012 to promote Malaysia as a preferred global destination for industry sponsored clinical research (ISR). CRM provides a range of services to enable and facilitate sponsors (primarily from the pharmaceutical and medical device industries) and contract research organizations (CROs) to initiate a wide spectrum of clinical trials in Malaysia.
CRM’s key functions encompasses three core components, the first of which is securing clinical trials. This is done through advertising and promotional activities, participation in key conferences, involvement in clinical trial distribution and strategic collaborations with major stakeholders. The second component involves closing the deals through a comprehensive feasibility study, convincing site review operation and implementation of an efficient financial, administration and approval process. The third component is conducting the trials. This is achieved through our high quality Study Coordinators and Principal Investigators, effective standard operating procedures, quality assurance of study sites and support services.
CRM Contact Details
Clinical Research Malaysia
Suite E-10-20, Amcorp Business Suites, Menara Melawangi,
Amcorp Trade Centre, No.18, Jalan Persiaran Barat,
46050 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
T: +603 7960 5153
F: +603 7932 1940
E: contact@clinicalresearch.my
W: www.clinicalresearch.my
Get connected socially,
facebook.com/clinicalresearchmalaysia
twitter.com/clinicalrsrchmy
youtube.com/ClinicalRsrchMy
linkedin.com/company/clinical-research-malaysia
Dr Akhmal Yusof, CEO of CRM sheds light on the capacity for all stages of clinical research in Malaysia. He discusses the importance of human resources for the country’s research…
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here